Literature DB >> 23334325

Oncogenic K-Ras requires activation for enhanced activity.

H Huang1, J Daniluk2, Y Liu3, J Chu3, Z Li4, B Ji5, C D Logsdon6.   

Abstract

Oncogenic Ras mutations are widely considered to be locked in a permanent 'On' state and 'constitutively active'. Yet, many healthy people have cells possessing mutant Ras without apparent harm, and in animal models mutant Ras causes transformation only after upregulation of Ras activity. Here, we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity. These data indicate that in addition to targeting K-Ras downstream effectors, interventions to reduce K-Ras activation may have important cancer-preventive value, especially in patients with oncogenic Ras mutations. As other small G proteins are regulated in a similar manner, this concept is likely to apply broadly to the entire Ras family of molecules.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334325      PMCID: PMC3923400          DOI: 10.1038/onc.2012.619

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  K-RAS mutation in the screening, prognosis and treatment of cancer.

Authors:  Barbara L Parsons; Fanxue Meng
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras.

Authors:  J de Rooij; J L Bos
Journal:  Oncogene       Date:  1997-02-06       Impact factor: 9.867

4.  Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups.

Authors:  Li Yan; Christopher McFaul; Nathan Howes; Jane Leslie; Gillian Lancaster; Theresa Wong; Jane Threadgold; Jonathan Evans; Ian Gilmore; Howard Smart; Martin Lombard; John Neoptolemos; William Greenhalf
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

Review 5.  Signal transduction by Ras-like GTPases: a potential target for anticancer drugs.

Authors:  M Spaargaren; J R Bischoff; F McCormick
Journal:  Gene Expr       Date:  1995

6.  Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras.

Authors:  Catherine Carrière; Alison L Young; Jason R Gunn; Daniel S Longnecker; Murray Korc
Journal:  Biochem Biophys Res Commun       Date:  2009-03-16       Impact factor: 3.575

7.  Robust acinar cell transgene expression of CreErT via BAC recombineering.

Authors:  Baoan Ji; Jian Song; Lilian Tsou; Yan Bi; Sebastian Gaiser; Richard Mortensen; Craig Logsdon
Journal:  Genesis       Date:  2008-08       Impact factor: 2.487

8.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.

Authors:  M Tada; M Ohashi; Y Shiratori; T Okudaira; Y Komatsu; T Kawabe; H Yoshida; R Machinami; K Kishi; M Omata
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

9.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.

Authors:  Carmen Guerra; Nieves Mijimolle; Alma Dhawahir; Pierre Dubus; Marta Barradas; Manuel Serrano; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

10.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.

Authors:  Carmen Guerra; Alberto J Schuhmacher; Marta Cañamero; Paul J Grippo; Lena Verdaguer; Lucía Pérez-Gallego; Pierre Dubus; Eric P Sandgren; Mariano Barbacid
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

View more
  68 in total

1.  A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.

Authors:  Bincy Philip; Christina L Roland; Jaroslaw Daniluk; Yan Liu; Deyali Chatterjee; Sobeyda B Gomez; Baoan Ji; Haojie Huang; Huamin Wang; Jason B Fleming; Craig D Logsdon; Zobeida Cruz-Monserrate
Journal:  Gastroenterology       Date:  2013-08-16       Impact factor: 22.682

Review 2.  Pancreatic cancer, inflammation, and microbiome.

Authors:  Constantinos P Zambirinis; Smruti Pushalkar; Deepak Saxena; George Miller
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

3.  Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition.

Authors:  Imran Siddiqui; Marco Erreni; Mohammad Azhar Kamal; Chiara Porta; Federica Marchesi; Samantha Pesce; Fabio Pasqualini; Silvia Schiarea; Chiara Chiabrando; Alberto Mantovani; Paola Allavena
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

Review 4.  Cholecystokinin and pancreatic cancer: the chicken or the egg?

Authors:  Jill P Smith; Travis E Solomon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

Review 5.  Pathogenesis of pancreatic cancer: lessons from animal models.

Authors:  L Charles Murtaugh
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

6.  Mitochondrial STAT3 contributes to transformation of Barrett's epithelial cells that express oncogenic Ras in a p53-independent fashion.

Authors:  Chunhua Yu; Xiaofang Huo; Agoston T Agoston; Xi Zhang; Arianne L Theiss; Edaire Cheng; Qiuyang Zhang; Alexander Zaika; Thai H Pham; David H Wang; Peter E Lobie; Robert D Odze; Stuart J Spechler; Rhonda F Souza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-06-04       Impact factor: 4.052

Review 7.  Reserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tract.

Authors:  Jason C Mills; Owen J Sansom
Journal:  Sci Signal       Date:  2015-07-14       Impact factor: 8.192

Review 8.  Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.

Authors:  Craig D Logsdon; Thiruvengadam Arumugam; Vijaya Ramachandran
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-09       Impact factor: 4.052

9.  The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis.

Authors:  Geou-Yarh Liou; Ligia Bastea; Alicia Fleming; Heike Döppler; Brandy H Edenfield; David W Dawson; Lizhi Zhang; Nabeel Bardeesy; Peter Storz
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

10.  Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum.

Authors:  Liang Wang; Chun-Han Lo; Xiaosheng He; Dong Hang; Molin Wang; Kana Wu; Andrew T Chan; Shuji Ogino; Edward L Giovannucci; Mingyang Song
Journal:  Gastroenterology       Date:  2020-04-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.